NCT03046550View on ClinicalTrials.gov

Study to Evaluate Safety and PK of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 20, 2017

Primary Completion Date

October 30, 2017

Study Completion Date

October 30, 2017

Conditions
Healthy
Interventions
DRUG

NTM-1634

NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).

DRUG

Placebo

placebo

Trial Locations (1)

78209

ICON Early Phase Services, LLC, San Antonio

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Alachua Government Services, Inc.

INDUSTRY

NCT03046550 - Study to Evaluate Safety and PK of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults | Biotech Hunter | Biotech Hunter